Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat

RA Mathot, EA van Schaick, MW Langemeijer, W Soudijn, DD Breimer, AP Ijzerman and M Danhof

Division of Pharmacology, Leiden/Amsterdam Center for Drug Research, University of Leiden, The Netherlands.

The purpose of the investigation was to develop a pharmacokinetic- pharmacodynamic model for the characterization of the cardiovascular effects of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) in individual normotensive rats. After the i.v. administration of 200 micrograms/kg (0.60 mumol/kg) of CPA, the time course of heart rate and arterial blood pressure was monitored in conjunction with serial blood sampling. Potential interference of the concentration- cardiovascular effect relationship by the development of acute tolerance or the formation of (inter)active metabolites was investigated by infusion of CPA with different rates and by determination of blood concentrations both by high-performance liquid chromatography and radioreceptor assay. In the individual rats the concentration-hemodynamic effect relationships were satisfactorily modeled according to the sigmoidal Emax pharmacodynamic model. For the negative chronotropic effect, the pharmacodynamic parameters proved to be independent of the infusion rate, indicating the absence of development of acute tolerance during the experiment. Potency (EC50) and intrinsic efficacy (Emax) were 2.7 +/- 0.5 ng/ml and -209 +/- 10 bpm, respectively (mean +/- S.E., n = 17). The concentrations of CPA as determined by the radioreceptor assay were identical to those determined by high-performance liquid chromatography, thereby excluding the formation of (inter)active metabolites. It is concluded that on the basis of this integrated pharmacokinetic-pharmacodynamic model, with the negative chronotropic effect as a pharmacodynamic endpoint, estimates of the potency and the intrinsic efficacy of adenosine A1 receptor agonists in vivo can be obtained after the administration of a single dose.

Volume 268, Issue 2, pp. 616-624, 02/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				T. J. van Steeg, J. Freijer, M. Danhof, and E. C. M. de Lange Mechanism-Based Pharmacodynamic Modeling of S(-)-Atenolol: Estimation of in Vivo Affinity for the {beta}1-Adrenoceptor with an Agonist-Antagonist Interaction Model J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1234 - 1242. [Abstract] [Full Text] [PDF]

				T. J. H. Bueters, M. J. A. Joosen, H. P. M. van Helden, A. P. IJzerman, and M. Danhof Adenosine A1 Receptor Agonist N6-Cyclopentyladenosine Affects the Inactivation of Acetylcholinesterase in Blood and Brain by Sarin J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1307 - 1313. [Abstract] [Full Text] [PDF]

				T. J. Bivalacqua, H. C. Champion, D. G. Lambert, and P. J. Kadowitz Vasodilator responses to adenosine and hyperemia are mediated by A1 and A2 receptors in the cat vascular bed Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1696 - R1709. [Abstract] [Full Text] [PDF]

				E. A. van Schaick, K. P. Zuideveld, H. E. Tukker, M. W. E. Langemeijer, A. P. Ijzerman, and M. Danhof Metabolic and Cardiovascular Effects of the Adenosine A1 Receptor Agonist N6-(p-Sulfophenyl)Adenosine in Diabetic Zucker Rats: Influence of the Disease on the Selectivity of Action J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 21 - 30. [Abstract] [Full Text]

				E. A. Van Schaick, R. A. A. Mathôt, J. M. Gubbens-Stibbe, M. W. E. Langemeijer, H. C. P. F. Roelen, A. P. Ijzerman, and M. Danhof 8-Alkylamino-Substituted Analogs of N6-Cyclopentyladenosine Are Partial Agonists for the Cardiovascular Adenosine A1 Receptors in Vivo J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 800 - 808. [Abstract] [Full Text]

				P. H. Van Der Graaf, E. A. Van Schaick, R. A. A. Mathôt, A. P. Ijzerman, and M. Danhof Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Effects of N6-Cyclopentyladenosine Analogs on Heart Rate in Rat: Estimation of in Vivo Operational Affinity and Efficacy at Adenosine A1 Receptors J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 809 - 816. [Abstract] [Full Text]

				E. Bonizzoni, S. Milani, E. Ongini, C. Casati, and A. Monopoli Modeling Hemodynamic Profiles by Telemetry in the Rat : A Study With A1 and A2a Adenosine Agonists Hypertension, April 1, 1995; 25(4): 564 - 569. [Abstract] [Full Text]